Search Page

1

Cite

Share

In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs.

Gagic Z, Ruzic D, Djokovic N, Djikic T, Nikolic K. Gagic Z, et al. Among authors: nikolic k. Front Chem. 2020 Jan 8;7:873. doi: 10.3389/fchem.2019.00873. eCollection 2019. Front Chem. 2020. PMID: 31970149 Free PMC article. Review.

Cite

Share

2

Cite

Share

Structure-based design of selective histone deacetylase 6 zinc binding groups.

Alves Avelar LA, Ruzic D, Djokovic N, Kurz T, Nikolic K. Alves Avelar LA, et al. Among authors: nikolic k. J Biomol Struct Dyn. 2020 Jul;38(11):3166-3177. doi: 10.1080/07391102.2019.1652687. Epub 2019 Aug 14. J Biomol Struct Dyn. 2020. PMID: 31382868

Cite

Share

3

Cite

Share

Multiple Targeting Approaches on Histamine H3 Receptor Antagonists.

Khanfar MA, Affini A, Lutsenko K, Nikolic K, Butini S, Stark H. Khanfar MA, et al. Among authors: nikolic k. Front Neurosci. 2016 May 30;10:201. doi: 10.3389/fnins.2016.00201. eCollection 2016. Front Neurosci. 2016. PMID: 27303254 Free PMC article. Review.

Cite

Share

4

Cite

Share

Deciphering Imidazoline Off-targets by Fishing in the Class A of GPCR field.

Djikic T, Vucicevic J, Laurila J, Radi M, Veljkovic N, Xhaard H, Nikolic K. Djikic T, et al. Among authors: nikolic k. Mol Inform. 2020 Jul;39(7):e1900165. doi: 10.1002/minf.201900165. Epub 2020 Mar 10. Mol Inform. 2020. PMID: 32078760

Cite

Share

5

Cite

Share

Bicyclic α-Iminophosphonates as High Affinity Imidazoline I₂ Receptor Ligands for Alzheimer's Disease.

Abás S, Rodríguez-Arévalo S, Bagán A, Griñán-Ferré C, Vasilopoulou F, Brocos-Mosquera I, Muguruza C, Pérez B, Molins E, Luque FJ, Pérez-Lozano P, de Jonghe S, Daelemans D, Naesens L, Brea J, Loza MI, Hernández-Hernández E, García-Sevilla JA, García-Fuster MJ, Radan M, Djikic T, Nikolic K, Pallàs M, Callado LF, Escolano C. Abás S, et al. Among authors: nikolic k. J Med Chem. 2020 Apr 9;63(7):3610-3633. doi: 10.1021/acs.jmedchem.9b02080. Epub 2020 Mar 19. J Med Chem. 2020. PMID: 32150414

Cite

Share

6

Cite

Share

Rational Drug Design of Antineoplastic Agents Using 3D-QSAR, Cheminformatic, and Virtual Screening Approaches.

Vucicevic J, Nikolic K, Mitchell JBO. Vucicevic J, et al. Among authors: nikolic k. Curr Med Chem. 2019;26(21):3874-3889. doi: 10.2174/0929867324666170712115411. Curr Med Chem. 2019. PMID: 28707592 Review.

Cite

Share

7

Cite

Share

Modulating Protein-Protein Interactions with Visible-Light-Responsive Peptide Backbone Photoswitches.

Albert L, Peñalver A, Djokovic N, Werel L, Hoffarth M, Ruzic D, Xu J, Essen LO, Nikolic K, Dou Y, Vázquez O. Albert L, et al. Among authors: nikolic k. Chembiochem. 2019 Jun 3;20(11):1417-1429. doi: 10.1002/cbic.201800737. Epub 2019 Apr 25. Chembiochem. 2019. PMID: 30675988 Free article.

Cite

Share

8

Cite

Share

Pharmacophore development and SAR studies of imidazoline receptor ligands.

Nikolic K, Agbaba D. Nikolic K, et al. Mini Rev Med Chem. 2012 Dec;12(14):1542-55. doi: 10.2174/138955712803832636. Mini Rev Med Chem. 2012. PMID: 22512575 Review.

Cite

Share

9

Cite

Share

One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug.

Hughes RE, Nikolic K, Ramsay RR. Hughes RE, et al. Among authors: nikolic k. Front Neurosci. 2016 Apr 25;10:177. doi: 10.3389/fnins.2016.00177. eCollection 2016. Front Neurosci. 2016. PMID: 27199640 Free PMC article. Review.

Cite

Share

10

Cite

Share

Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease.

Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipic S, Agbaba D, Esteban G, Unzeta M, Nikolic K, Butini S, Marco-Contelles J. Ismaili L, et al. Among authors: nikolic k. Prog Neurobiol. 2017 Apr;151:4-34. doi: 10.1016/j.pneurobio.2015.12.003. Epub 2016 Jan 18. Prog Neurobiol. 2017. PMID: 26797191 Review.

Cite

Share